Adjusted EBITDA before one time and exceptional item stood at Rs 439 crores at 16% against Rs. 393 crores in the previous financial year.
Commenting on the results, Parmod Sagar – MD & CEO of RHI Magnesita India said, “In FY23, we remained committed to the Indian market and ramped up our capacity with the acquisition of Dalmia OCL and Hi-Tech Chemicals. These acquisitions aim to help us serve our customers with a local-for-local approach and evolve India as a hub to serve other regions. We are well on track to achieve our integration synergy targets through these acquisitions, and we are excited for the future.
On a consolidated basis, the total income for the quarter ending March 31, 2023, stood at Rs. 881 crores, 49% growth Q-o-Q as against Rs. 592 crores in the quarter of March 2022.
Adjusted EBITDA before one time and exceptional item stood at Rs 118 crores at 13.4% Vs Rs. 140 crores in the same quarter in the previous year.
The Board of Directors has proposed a dividend of Rs. 2.50 per share (250% on equity share of par value of Re 1) subject to the approval of the members of the Company in the Annual General Meeting.